Dopaminergic medications used in the treatment of patients with Parkinson's disease are
associated with motor and non-motor behavioural side-effects, such as dyskinesias and …

Despite being considered primarily a mood disorder, major depressive disorder (MDD) is
characterized by cognitive and decision making deficits. Recent research has employed …

The serotonin (5-HT, 5-hydroxytryptamine) system has been implicated in the pathogenesis
of major depressive disorder (MDD). The case for its contribution to the therapeutic efficacy …

Vagus nerve stimulation (VNS) is an adjunctive treatment for resistant epilepsy and
depression. Electrophysiological recordings in the rat brain have already shown that chronic …

Tourette syndrome (TS) is thought to involve dopaminergic disturbances, but the nature of
those disturbances remains controversial. Existing hypotheses suggest that TS involves 1) …

Neuropsychiatric disorders are multifactorial disorders with diverse aetiological factors.
Identifying treatment targets is challenging because the diseases are resulting from …

Over the last decade accumulating evidence suggests that brain dopamine (DA) has a role
in depression, particularly given the high comorbidity of depression with Parkinson's …

Despite the well-documented beneficial effect of exercise on stress coping and depression
treatment, its underlying neurobiological mechanism remains unclear. This is further …

Tourette syndrome (TS) prominently involves dopaminergic disturbances, but the precise
nature of those disturbances has remained elusive. A substantial body of empirical work and …

Agomelatine is a melatonergic MT1/MT2 agonist and a serotonin (5-HT) 5-HT 2C antagonist.
The effects of 2-day and 14-day administration of agomelatine were investigated on the …